Page last updated: 2024-08-25

zoledronic acid and Atherosclerosis

zoledronic acid has been researched along with Atherosclerosis in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (33.33)29.6817
2010's1 (33.33)24.3611
2020's1 (33.33)2.80

Authors

AuthorsStudies
Chen, L; Fu, X; Jiang, J; Yang, J; Yang, Z; Yu, C; Yu, X1
Brazier, J; Brown, WT; Campbell, SE; D'Agostino, RB; Gordon, LB; Kieran, MW; Kleinman, ME; Massaro, J1
Avanzati, A; Campagna, MS; De Paola, V; Franci, B; Gennari, L; Gozzetti, A; Lauria, F; Marchini, E; Martini, G; Merlotti, D; Nuti, R; Salvadori, S; Tozzi, M1

Other Studies

3 other study(ies) available for zoledronic acid and Atherosclerosis

ArticleYear
Small molecule-assisted assembly of multifunctional ceria nanozymes for synergistic treatment of atherosclerosis.
    Nature communications, 2022, 11-01, Volume: 13, Issue:1

    Topics: Atherosclerosis; Humans; Inflammation; Nanoparticles; Reactive Oxygen Species; Zoledronic Acid

2022
Impact of farnesylation inhibitors on survival in Hutchinson-Gilford progeria syndrome.
    Circulation, 2014, Jul-01, Volume: 130, Issue:1

    Topics: Adolescent; Adult; Alkyl and Aryl Transferases; Atherosclerosis; Cause of Death; Child; Child, Preschool; Clinical Trials as Topic; Cohort Studies; Dimethylallyltranstransferase; Diphosphonates; Drug Therapy, Combination; Female; Genes, Dominant; Genotype; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Imidazoles; Kaplan-Meier Estimate; Lamin Type A; Male; Multicenter Studies as Topic; Nuclear Proteins; Piperidines; Pravastatin; Progeria; Proportional Hazards Models; Protein Precursors; Protein Prenylation; Pyridines; Treatment Outcome; Young Adult; Zoledronic Acid

2014
The effects of zoledronic acid on serum lipids in multiple myeloma patients.
    Calcified tissue international, 2008, Volume: 82, Issue:4

    Topics: Aged; Aged, 80 and over; Atherosclerosis; Bone Density Conservation Agents; Cholesterol, HDL; Collagen; Diphosphonates; Female; Humans; Imidazoles; Lipids; Male; Middle Aged; Multiple Myeloma; Treatment Outcome; Zoledronic Acid

2008